{"a":[{"_":"Epicrispr raises $90M to rewrite treatment of rare muscle disease","$":{"href":"/biotech/epicrispr-bags-90m-rewrite-treatment-rare-muscle-disease","hreflang":"en"}}]}

Summary

Epicrispr Biotechnologies raised $90 million in Series C funding led by Sanofi Ventures to advance its pipeline of epigenetic medicines, with an early-phase candidate targeting facioscapulohumeral muscular dystrophy.